Roche Holding AG

🇨🇭Switzerland

Country: 🇨🇭Switzerland

Ownership: Public

Established: 1896-01-15

Employees: 103.6K

Market Cap: $270.5B

Website: http://www.roche.com

Clinical Trials

A Study of Ribavirin in Combination With PEGASYS (Peginterferon Alfa-2a (40KD))in Patients With Chronic Hepatitis C

Phase 4

Completed

Conditions: Hepatitis C, Chronic

Interventions: Drug: peginterferon alfa-2a [Pegasys]
Drug: ribavirin

First Posted Date: 2009-06-17

Last Posted Date: 2016-01-20

Lead Sponsor: Hoffmann-La Roche

Target Recruit Count: 6661

Registration Number: NCT00922779

A Study of Mircera in Renal Anemia Among Filipino Chronic Kidney Disease Patients

Phase 4

Completed

Conditions: Anemia

Interventions: Drug: methoxy polyethylene glycol-epoetin beta [Mircera]

First Posted Date: 2009-06-17

Last Posted Date: 2016-11-02

Lead Sponsor: Hoffmann-La Roche

Target Recruit Count: 28

Registration Number: NCT00922610

A Study of PEGASYS (Peginterferon Alfa-2a (40KD)) in Combination With Adefovir or Entecavir in Patients With HBeAg-Positive Chronic Hepatitis B

Phase 4

Completed

Conditions: Hepatitis B, Chronic

Interventions: Drug: Placebo
Drug: Entecavir
Drug: Adefovir
Drug: peginterferon alfa-2a [Pegasys]

First Posted Date: 2009-06-17

Last Posted Date: 2017-04-10

Lead Sponsor: Hoffmann-La Roche

Target Recruit Count: 280

Registration Number: NCT00922207

Locations: 🇨🇳
National Taiwan Uni Hospital; Gastro-Enterology Dept., Taipei, Taiwan
🇨🇳
Taipei Veterans General Hospital; Gastroenterology Division, Taipei, Taiwan
🇨🇳
Kaohsiung Medical Uni Chung-Ho Memorial Hospital; Dept of Internal Medicine, Kaohsiung, Taiwan

and more 6 locations

A Study of Once Monthly Subcutaneous Mircera in Patients With Chronic Renal Anemia Not on Dialysis

Phase 4

Completed

Conditions: Anemia

Interventions: Drug: methoxy polyethylene glycol-epoetin beta [Mircera]

First Posted Date: 2009-06-17

Last Posted Date: 2017-07-13

Lead Sponsor: Hoffmann-La Roche

Target Recruit Count: 191

Registration Number: NCT00922116

Locations: 🇰🇷
Kyungpook National Uni Hospital; Internal Medicine, Daegu, Korea, Republic of
🇰🇷
Inje University Busan Paik Hospital; Nephrology, Busan, Korea, Republic of
🇰🇷
Chungnam National Uni Hospital; Nephrology, Daejeon, Korea, Republic of

and more 7 locations

A Study of Taspoglutide Versus Pioglitazone in Patients With Type 2 Diabetes

Phase 3

Completed

Conditions: Diabetes Mellitus Type 2

Interventions: Drug: taspoglutide
Drug: pioglitazone

First Posted Date: 2009-05-28

Last Posted Date: 2016-11-02

Lead Sponsor: Hoffmann-La Roche

Target Recruit Count: 756

Registration Number: NCT00909597

A Study Of Tocilizumab in Patients With Moderate to Severe Active Rheumatoid Arthritis Who Have an Inadequate Response to or Are Unable to Tolerate Biologic and Non-Biologic Disease-modifying Antirheumatic Drugs (DMARDs)

Phase 3

Completed

Conditions: Rheumatoid Arthritis

Interventions: Drug: tocilizumab [RoActemra/Actemra]
Drug: Nonbiologic DMARDs of investigator's choice

First Posted Date: 2009-04-30

Last Posted Date: 2012-10-25

Lead Sponsor: Hoffmann-La Roche

Target Recruit Count: 886

Registration Number: NCT00891020

A Study of Bevacizumab (Avastin) Versus Placebo in Combination With Capecitabine (Xeloda) and Cisplatin as First-Line Therapy for Advanced Gastric Cancer

Phase 3

Completed

Conditions: Gastric Cancer

Interventions: Drug: Placebo
Drug: Bevacizumab
Drug: Capecitabine
Drug: Cisplatin

First Posted Date: 2009-04-24

Last Posted Date: 2017-03-01

Lead Sponsor: Hoffmann-La Roche

Target Recruit Count: 202

Registration Number: NCT00887822

A Study Comparing Infusion Rates of Tocilizumab in Patients With Moderate to Severe Rheumatoid Arthritis

Phase 2

Completed

Conditions: Rheumatoid Arthritis

Interventions: Drug: tocilizumab [RoActemra/Actemra]

First Posted Date: 2009-04-23

Last Posted Date: 2014-10-22

Lead Sponsor: Hoffmann-La Roche

Target Recruit Count: 76

Registration Number: NCT00887341

A Study of Herceptin (Trastuzumab)and Biomarkers in Patients With HER2-Positive Metastatic Breast Cancer

Phase 2

Completed

Conditions: Breast Cancer

Interventions: Drug: Standard taxane therapy
Drug: capecitabine [Xeloda]
Drug: trastuzumab [Herceptin]

First Posted Date: 2009-04-22

Last Posted Date: 2018-03-29

Lead Sponsor: Hoffmann-La Roche

Target Recruit Count: 33

Registration Number: NCT00885755

Locations: 🇬🇧
Christie Hospital; Breast Cancer Research Office, Manchester, United Kingdom
🇦🇺
Mount Medical Center, Perth, Western Australia, Australia
🇸🇪
Karolinska Hospital; Oncology - Radiumhemmet, Stockholm, Sweden

and more 10 locations

Influenza Resistance Information Study

Completed

Conditions: Influenza

Interventions: Drug: Oseltamivir

First Posted Date: 2009-04-20

Last Posted Date: 2016-10-19

Lead Sponsor: Hoffmann-La Roche

Target Recruit Count: 4561

Registration Number: NCT00884117

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy